miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer
Hauptverfasser: van Jaarsveld, Marijn T. M., van Kuijk, Patricia F., Boersma, Antonius W. M., Helleman, Jozien, van IJcken, Wilfred F., Mathijssen, Ron H. J., Pothof, Joris, Berns, Els M. J. J., Verweij, Jaap, Wiemer, Erik A. C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://ncbi.nlm.nih.gov/pubmed/26576679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0464-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge